Abstract:Abstract Background Pulmonary arterial hypertension (PAH) is characterized by an increase in pulmonary vascular resistance, leading to increased afterload and right-sided heart failure. It is important to routinely assess disease progression and treatment response, with echocardiography an increasingly recognized important component of risk assessment. Parenteral prostacyclin therapy has been shown to be associated with improvements in right-sided cardiac structure and function, which are prognostic in PAH. Purpose To describe changes in right-sided cardiac structural and functional parameters after a short course of parenteral treprostinil. Methods The EXPEDITE trial (NCT03497689) was a 16-week open-label study of WHO Functional Class (FC) II or III patients with PAH designed to assess short-term (expedited) induction therapy with parenteral treprostinil over 2-8 weeks, to facilitate transition to comparable doses of oral treprostinil. The subset of patients in the per-protocol population that had clinical and/or echocardiographic data available at both baseline (prior to initiation of parenteral treprostinil) and end of induction (2-8 weeks) were included for analysis. Changes in each parameter were analyzed using the non-parametric Wilcoxon signed-rank test. Results In the per-protocol population of EXPEDITE (n=29), the median age was 56 years, 62% were female, and 79% were white. At baseline, 52% were classified as WHO FC II and 48% WHO FC III. Patients were on either no (n=6, 21%), 1 (n=11, 38%), or 2 (n=12, 41%) background PAH therapies. The end of the parenteral treprostinil induction period occurred at Week 2 (n=1), Week 4 (n=5), or Week 8 (n=23); the median (interquartile range) parenteral treprostinil dose achieved was 23.8 (20, 39.3) ng/kg/min. Median changes from baseline to the end of the parenteral treprostinil induction period for this analysis are shown in Table 1. There were directional changes for most measures of right-sided cardiac structure and function that reflected overall improvement; two key markers of cardiac function, cardiac output and NT-proBNP significantly improved. Conclusions In this trial of expedited parenteral treprostinil induction, we saw favorable directional trends in changes in right heart structure and function that were achieved in 8 weeks or less, including some statistically-significant parameters known to have prognostic value in PAH. The relatively rapid improvements we observed in this small cohort may signal important changes in risk status, and support treatment guidelines emphasizing importance of early improvement in the first 3-6 months following treatment. Furthermore, changes in cardiac structure and function often occur before other clinically-evident indicators of disease progression, and early response to treatment has been shown to impact long-term outcomes in patients with PAH. Larger studies with short-term serial right heart imaging assessment to confirm findings are warranted.Table 1

Can Treprostinil-Induced Early Gastrointestinal Side Effects Serve As Predictors of Pulmonary Arterial Hypertension Prognosis?

Efficacy of oral treprostinil for treating pulmonary arterial hypertension: a systematic review and meta-analysis

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension A Double-Blind Placebo-controlled Clinical Trial

The safety and efficacy of treprostinil for the treatment of pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials

Effect of a short course of parenteral treprostinil therapy on right heart structure and function in pulmonary arterial hypertension

Efficacy and Determinants of Response to Inhaled Treprostinil in Pulmonary Hypertension - Interstitial Lung Disease

Inhaled Treprostinil in Pulmonary Hypertension Associated with Lung Disease

Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review

Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.

Prognostic value of echocardiographic changes in patients with pulmonary arterial hypertension receiving parenteral prostacyclin therapy

PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis

Evaluating the Impact of Pulmonary Arterial Hypertension Therapies on Pericardial Effusion and Patient Survival

Pulmonary Vasodilator Therapy Is Associated with Decreased Mortality in Patients with Chronic Lung Disease and Severe Pulmonary Hypertension

Targeted Drugs for Pulmonary Arterial Hypertension: a Network Meta-Analysis of 32 Randomized Clinical Trials.

Reversal of Right Ventricular Hypertrophy and Dysfunction by Prostacyclin in a Rat Model of Severe Pulmonary Arterial Hypertension

ORAL TREPROSTINIL TREATMENT IS ASSOCIATED WITH IMPROVED SURVIVAL IN PULMONARY ARTERIAL HYPERTENSION PARTICIPANTS IN FREEDOM-EV AND THE FREEDOM-EV OPEN-LABEL EXTENSION STUDY

Use of inhaled treprostinil in patients with interstitial lung disease and pulmonary hypertension: to boldly go where no other pulmonary vasodilator has gone before?

Acute vasoreactivity testing predicts outcome of idiopathic pulmonary arterial hypertension patients with a negative acute response

Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension

Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results

Long-term safety and survival time under subcutaneous treprostinil treatment in patients with severe chronic thromboembolic pulmonary hypertension (CTEPH)